NASDAQ · XFOR
X4 Pharmaceuticals, Inc.
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
Loading market information…
AMEX · SER · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Serina Therapeutics, Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$0.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Serina Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 24, 2025 |
| -$0.27-164.29% vs estimate |
| -$14.00K |
| Q3 2024 | Nov 12, 2024 | $0.13 | $14.00K |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
$0.96-$0.05 (-4.53%)
Telomir Pharmaceuticals, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 38.97% below the high.
$1.60+$0.07 (+4.58%)
INmune Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$1.94-$0.07 (-3.48%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.55% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$0.74-$0.02 (-2.49%)
Barinthus Biotherapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$1.50-$0.10 (-6.25%)
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
$0.62+$0.02 (+2.48%)
Genenta Science S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 80.32% below the high.
